Exelixis | EXEL - 資産





資産 変化する 日付
Acadia Pharmaceuticals USD 1.61B 41.04M 2026-03
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
Akebia Therapeutics USD 362.52M 14.04M 2026-03
Amgen USD 92.5B 1.92B 2026-03
AstraZeneca USD 114.02B 59M 2026-03
Bayer EUR 107.94B 3.4B 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Cytokinetics USD 1.27B 151.06M 2026-03
Eisai JPY 1.45T 37.11B 2026-03
Eli Lilly USD 116.58B 4.1B 2026-03
Esperion Therapeutics USD 462.53M 3.36M 2026-03
Exelixis USD 2.59B 250.83M 2026-03
Genmab DKK 12.87B 5.85B 2025-12
Glaxosmithkline GBP 82.34B 102.25M 2025-12
Incyte USD 7.34B 381.14M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
MacroGenics USD 217.87M 38.97M 2026-03
Merck USD 128.68B 8.18B 2026-03
Moderna USD 11.49B 850M 2026-03
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Novartis USD 118.53B 7.58B 2026-03
Pfizer USD 207.62B 542M 2026-03
Puma Biotechnology USD 202.86M 7.95M 2025-09
Sanofi EUR 126.81B 25.48B 2025-12
Takeda JPY 15.45T 44.34B 2026-03
Ultragenyx Pharmaceutical USD 1.3B 236M 2026-03
Xencor USD 736.85M 138.65M 2026-03